Global Information
회사소개 | 문의

간염 치료제 개발 파이프라인 리뷰

Hepatitis Drug Development Pipeline Review, 2018

리서치사 GBI Research
발행일 2018년 06월 상품 코드 537171
페이지 정보 영문 133 Pages
가격
US $ 3,995 ₩ 4,509,500 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 9,019,100 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 13,528,600 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


간염 치료제 개발 파이프라인 리뷰 Hepatitis Drug Development Pipeline Review, 2018
발행일 : 2018년 06월 페이지 정보 : 영문 133 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

각종 간염(A형, B형, C형, D형 간염) 치료제의 임상시험 및 개발 동향에 대해 분석했으며, 질환 개요, 현재까지 치료제 개발·출시 상황, 현재 임상시험 및 심사중인 주요 파이프라인 제품, 휴지중·중지된 프로젝트 개요, 향후 임상시험 방향성과 실현 전망 등의 정보를 전해드립니다.

1. 분석 개요

2. 주요 요약

3. 목차 및 도표

4. 서론

  • 분석 범위
  • A형 간염 : 개요
  • B형 간염 : 개요
  • C형 간염 : 개요
  • D형 간염 : 개요

5. 치료제 개발

  • A형 간염
  • B형 간염
  • C형 간염
  • D형 간염

6. 치료제 평가

7. 치료제 개발에 참여하고 있는 기업

8. 현재 휴지중인 프로젝트

9. 개발이 중지된 프로젝트

10. 제품 개발 마일스톤

11. 부록

도표

KSM 17.08.22

영문목차

Summary:

Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Hepatitis A and E are typically caused by ingestion of contaminated food or water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes.

Risk factors include a weakened immune system and use of injected or non-injected illicit drugs. Symptoms of hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite and pain in the abdomen.

Hepatitis B and hepatitis D infection typically occur as a result of contact with infected body fluids. Transmission of hepatitis B can occur via sexual contact, injection drug use or transfusions of contaminated blood and blood products. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting and abdominal pain.

Hepatitis D infection only occurs in persons previously infected with hepatitis B, as the hepatitis D virus can only replicate in the presence of hepatitis B. The co-infection of hepatitis B and hepatitis D is associated with greater disease severity than hepatitis B infection alone.

Companies operating in this pipeline space include Cadila Healthcare and Chongqing Zhifei Biological Products.

This report "Hepatitis Drug Development Pipeline Review, 2018" provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features dormant and discontinued products.

Scope:

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Hepatitis Report Coverage
  • 2.2. Hepatitis A - Overview
  • 2.3. Hepatitis B - Overview
  • 2.4. Hepatitis D - Overview
  • 2.5. Hepatitis E - Overview

3. Therapeutics Development

  • 3.1. Hepatitis A
  • 3.2. Hepatitis B
  • 3.3. Hepatitis D
  • 3.4. Hepatitis E

4. Therapeutics Assessment

  • 4.1. Hepatitis A
  • 4.2. Hepatitis B
  • 4.3. Hepatitis D
  • 4.4. Hepatitis E

5. Companies Involved in Therapeutics Development

  • 5.1. Hepatitis A
  • 5.2. Hepatitis B
  • 5.3. Hepatitis D
  • 5.4. Hepatitis E

6. Dormant Projects

  • 6.1. Hepatitis A
  • 6.2. Hepatitis B
  • 6.3. Hepatitis D
  • 6.4. Hepatitis E

7. Discontinued Products

  • 7.1. Hepatitis B

8. Product Development Milestones

  • 8.1. Hepatitis B
  • 8.2. Hepatitis D
  • 8.3. Hepatitis E

9. Appendix

  • 9.1. Methodology
  • 9.2. Coverage
  • 9.3. Secondary Research
  • 9.4. Primary Research
  • 9.5. Expert Panel Validation
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Hepatitis A
  • Table 2: Number of Products under Development by Companies, Hepatitis A
  • Table 3: Number of Products under Development by Universities/Institutes, Hepatitis A
  • Table 4: Products under Development by Companies, Hepatitis A
  • Table 5: Products under Development by Universities/Institutes, Hepatitis A
  • Table 6: Number of Products under Development for Hepatitis B
  • Table 7: Number of Products under Development by Companies, Hepatitis B
  • Table 8: Number of Products under Development by Universities/Institutes, Hepatitis B
  • Table 9: Products under Development by Companies, Hepatitis B
  • Table 10: Products under Development by Universities/Institutes, Hepatitis B
  • Table 11: Number of Products under Development for Hepatitis D
  • Table 12: Number of Products under Development by Companies, Hepatitis D
  • Table 13: Number of Products under Development by Universities/Institutes, Hepatitis D
  • Table 14: Products under Development by Companies, Hepatitis D
  • Table 15: Products under Development by Universities/Institutes, Hepatitis D
  • Table 16: Number of Products under Development for Hepatitis E
  • Table 17: Number of Products under Development by Companies, Hepatitis E
  • Table 18: Number of Products under Development by Universities/Institutes, Hepatitis E
  • Table 19: Products under Development by Companies, Hepatitis E
  • Table 20: Products under Development by Universities/Institutes, Hepatitis E
  • Table 21: Number of Products by Stage and Route of Administration, Hepatitis A
  • Table 22: Number of Products by Stage and Molecule Type, Hepatitis A
  • Table 23: Number of Products by Stage and Target, Hepatitis B
  • Table 24: Number of Products by Stage and Mechanism of Action, Hepatitis B
  • Table 25: Number of Products by Stage and Route of Administration, Hepatitis B
  • Table 26: Number of Products by Stage and Molecule Type, Hepatitis B
  • Table 27: Number of Products by Stage and Target, Hepatitis D
  • Table 28: Number of Products by Stage and Mechanism of Action, Hepatitis D
  • Table 29: Number of Products by Stage and Route of Administration, Hepatitis D
  • Table 30: Number of Products by Stage and Molecule Type, Hepatitis D
  • Table 31: Number of Products by Stage and Target, Hepatitis E
  • Table 32: Number of Products by Stage and Mechanism of Action, Hepatitis E
  • Table 33: Number of Products by Stage and Route of Administration, Hepatitis E
  • Table 34: Number of Products by Stage and Molecule Type, Hepatitis E
  • Table 35: Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd
  • Table 36: Hepatitis A - Pipeline by Cadila Healthcare Ltd
  • Table 37: Hepatitis A - Pipeline by China National Pharmaceutical Group Corp
  • Table 38: Hepatitis A - Pipeline by Indian Immunologicals Ltd
  • Table 39: Hepatitis A - Pipeline by Sinovac Biotech Ltd
  • Table 40: Hepatitis B - Pipeline by Abivax SA
  • Table 41: Hepatitis B - Pipeline by AiCuris GmbH & Co KG
  • Table 42: Hepatitis B - Pipeline by AIMM Therapeutics BV
  • Table 43: Hepatitis B - Pipeline by Akshaya Bio Inc
  • Table 44: Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc
  • Table 45: Hepatitis B - Pipeline by Altimmune Inc
  • Table 46: Hepatitis B - Pipeline by Altravax Inc
  • Table 47: Hepatitis B - Pipeline by Amarna Therapeutics BV
  • Table 48: Hepatitis B - Pipeline by Arbutus Biopharma Corp
  • Table 49: Hepatitis B - Pipeline by Arcturus Therapeutics Ltd
  • Table 50: Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc
  • Table 51: Hepatitis B - Pipeline by Ascentage Pharma Group Corp Ltd
  • Table 52: Hepatitis B - Pipeline by Assembly Biosciences Inc
  • Table 53: Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC
  • Table 54: Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd
  • Table 55: Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd
  • Table 56: Hepatitis B - Pipeline by Benitec Biopharma Ltd
  • Table 57: Hepatitis B - Pipeline by Biological E Ltd
  • Table 58: Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc
  • Table 59: Hepatitis B - Pipeline by Biotron Ltd
  • Table 60: Hepatitis B - Pipeline by Bolder Biotechnology Inc

List of Figures

  • Figure 1: Number of Products under Development for Hepatitis A
  • Figure 2: Number of Products under Development by Companies, Hepatitis A
  • Figure 3: Number of Products under Development for Hepatitis B
  • Figure 4: Number of Products under Development by Companies, Hepatitis B
  • Figure 5: Number of Products under Development by Universities/Institutes, Hepatitis B
  • Figure 6: Number of Products under Development for Hepatitis D
  • Figure 7: Number of Products under Development by Companies, Hepatitis D
  • Figure 8: Number of Products under Development for Hepatitis E
  • Figure 9: Number of Products under Development by Companies, Hepatitis E
  • Figure 10: Number of Products by Stage and Routes of Administration, Hepatitis A
  • Figure 11: Number of Products by Molecule Types, Hepatitis A
  • Figure 12: Number of Products by Stage and Molecule Types, Hepatitis A
  • Figure 13: Number of Products by Top 10 Targets, Hepatitis B
  • Figure 14: Number of Products by Stage and Top 10 Targets, Hepatitis B
  • Figure 15: Number of Products by Top 10 Mechanism of Actions, Hepatitis B
  • Figure 16: Number of Products by Stage and Top 10 Mechanism of Actions, Hepatitis B
  • Figure 17: Number of Products by Routes of Administration, Hepatitis B
  • Figure 18: Number of Products by Stage and Routes of Administration, Hepatitis B
  • Figure 19: Number of Products by Top 10 Molecule Types, Hepatitis B
  • Figure 20: Number of Products by Stage and Top 10 Molecule Types, Hepatitis B
  • Figure 21: Number of Products by argets, Hepatitis D
  • Figure 22: Number of Products by Stage and Targets, Hepatitis D
  • Figure 23: Number of Products by Mechanism of Actions, Hepatitis D
  • Figure 24: Number of Products by Stage and Mechanism of Actions, Hepatitis D
  • Figure 25: Number of Products by Routes of Administration, Hepatitis D
  • Figure 26: Number of Products by Stage and Routes of Administration, Hepatitis D
  • Figure 27: Number of Products by Molecule Types, Hepatitis D
  • Figure 28: Number of Products by Stage and Molecule Types, Hepatitis D
  • Figure 29: Number of Products by Molecule Types, Hepatitis E
  • Figure 30: Number of Products by Stage and Molecule Types, Hepatitis E
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research